免疫调节治疗在慢加急性肝衰竭早期患者中应用的临床研究

龚学艳; 胡泰洪; 关文锋; 吴兴华; 吴宇航; 李志伟; 刘明; 刘臻

doi:10.3969/j.issn.1671-038X.2017.05.13

免疫调节治疗在慢加急性肝衰竭早期患者中应用的临床研究

- 1. 暨南大学附属江门中医院江门市五邑中医院感染科, 广东江门 529000;
- 2. 暨南大学附属江门中医院江门市五邑中医院脑病科, 广东江门 529000
基金项目:
广东省江门市科技计划项目（No：20150020002888）

详细信息

作者简介:
龚学艳,女,硕士,研究方向:肝衰竭及其并发症的防治

通讯作者: 龚学艳,E-mail:sixize@163.com

中图分类号: R575.3

收稿日期: 2016-12-09

Clinical study on application of immunomodulatory therapy in patients with early acute-on-chronic liver failure

- 1. Department of Infectious Diseases, the Affiliated Jiangmen Traditional Chinese Medicine Hospital of Jinan University, Jiangmen 529000, China;
- 2. Department of Neurology, the Affiliated Jiangmen Traditional Chinese Medicine Hospital of Jinan University, Jiangmen 529000, China

More Information

Corresponding author: GONG Xue-yan, E-mail: sixize@163.com

Received Date: 09 December 2016

摘要

摘要: [目的]探讨免疫调节治疗在HBV相关慢加急性肝衰竭早期患者中的疗效。[方法]将80例HBV相关慢加急性肝衰竭早期患者随机分为对照组（40例）和实验组（40例），对照组患者给予常规内科治疗，实验组患者给予在常规治疗的基础上加用地塞米松、静注免疫球蛋白的治疗方案，2组患者常规治疗疗程均为4周。2组患者分别于治疗前及治疗1周、4周后检测总胆红素、白蛋白及凝血酶原活动度，并于治疗4 w后进行疗效判断。[结果]治疗4周后，实验组患者总胆红素较对照组明显降低，实验组患者白蛋白及凝血酶原活动度较对照组升高，差异均具有统计学意义（P<0.05）；实验组总有效率显著高于对照组（P<0.05）。[结论]在常规内科治疗基础上，给予地塞米松联合静注免疫球蛋白治疗HBV相关慢加急性肝衰竭早期患者，可以有效改善患者肝功能，显著提高患者的存活率，降低其病死率。
- 免疫调节治疗 /
- 慢加急性肝衰竭 /
- 地塞米松 /
- 静注免疫球蛋白
Abstract: [Objective] To investigate the efficiency of immunomodulatory therapy in patients with early hepatitis B virus related acute-on-chronic liver failure.[Methods] 80 patients with early hepatitis B virus related acute-on-chronic liver failure were randomly divided into the treatment group and the control group, 40 patients in each group.The control group was treated with routine medical treatment.The treatment group was given dexamethasone(DXM) and human intravenous immunoglobulin(IVIG) on the basis of the routine medical treatment.The total routine medical treatment couse of two groups was 4 weeks.The total bilirubin(TBIL), albumin(ALB) and prothrombin activity(PTA) were detected before treatment and 1, 4 weeks after treatment respectively.[Results] After 4 weeks, the level of TBIL decreased more in treatment group than that in control group, while the levels of ALB and PTA increased more than that of the controls(P<0.05).The effective rate of the treatment group was significantly higher than that of control group(P<0.05).[Conclusion] The immunomodulatory therapy can effectively improve the liver function of patients with early hepatitis B virus related acute-on-chronic liver failure.
- immunomodulatory therapy /
- acute-on-chronic liver failure /
- dexamethasone /
- human intravenous immunoglobulin

HTML全文

参考文献(10)

[1]	中华医学会感染病学分会肝衰竭与人工肝学组, 中华医学会肝病学分会重型肝病与人工肝学组.肝衰竭诊疗指南[J].中华临床感染病杂志, 2012, 5(6):321-327.
[2]	Lee W M.Acute liver failure[J].Semin Respir Crit Care Med, 2012, 33(1):36-45.
[3]	冯铁柱, 岑枝梅, 张琼, 等.静脉注射人免疫球蛋白治疗重型肝炎的临床研究[J].中华实验和临床感染病杂志, 2014, 8(4):517-521.
[4]	Fujiwara K, Yasui S, Okitsu K, et al.The requirement for a sufficient period of corticosteroid treatment in combination with nucleoside analogue for severe acute exacerbation of chronic hepatitis B[J].J Gastroenterol, 2010, 45:1255-1262.
[5]	Zhang X Q, Jiang L, You J P, et al.Efficacy of shortterm dexamethasone therapy in acute-on-chronic preliver failu re[J].Hepatol Res, 2011, 41:46-53.
[6]	Fujiwara K, Yasui S, Yokosuka O, et al.Corticosteroid and nucleoside analogue for hepatitis B virus-related acute liver failure[J].World J Gastroenterol, 2015, 21:10485-10486.
[7]	Bockmann J H, Dandri M, Lüth S, et al.Combined glucocorticoid and antiviral therapy of hepatitis B virus-related liver failure[J].World J Gastroenterol, 2015, 21:2214-2219.
[8]	Fujiwara K, Yasui S, Okitsu K, et al.The requirement for a sufficient period of corticosteroid treatment in combination with nucleoside analogue for severe acute exacerbation of chronic hepatitis B[J].J Gastroenterol, 2010, 45:1255-1262.
[9]	Delves PJ, Roitt IM.The immune system.Second of two parts[J].N Engl J Med, 2000, 343:108-117.
[10]	Bertoletti A, Ferrari C.Innate and adaptive immune responses in chronic hepatitis B virus infections:towards restoration of immune control of viral infection[J].Gut, 2012, 61:1754-1764.